

ORIGINAL INVESTIGATION

Open Access

Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser¹¹⁷⁷/Thr⁴⁹⁷ of endothelial nitric oxide synthase in diabetic mice

Sachiko Matsumoto¹, Michio Shimabukuro^{2*}, Daiju Fukuda², Takeshi Soeki¹, Ken Yamakawa³, Hiroaki Masuzaki³ and Masataka Sata¹

Abstract

Background: Azilsartan, an angiotensin II type 1 (AT1) receptor blocker (ARB), has a higher affinity for and slower dissociation from AT1 receptors and shows stronger inverse agonism compared to other ARBs. Possible benefits of azilsartan in diabetic vascular dysfunction have not been established.

Methods: We measured vascular reactivity of aortic rings in male KKAY diabetic mice treated with vehicle, 0.005% azilsartan, or 0.005% candesartan cilexetil for 3 weeks. Expression of markers of inflammation and oxidative stress was measured using semiquantitative RT-PCR in the vascular wall, perivascular fat, and skeletal muscle. Phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser¹¹⁷⁷ and Thr⁴⁹⁵ was measured using Western blotting, and the ratio of phosphorylation at Ser¹¹⁷⁷ to phosphorylation at Thr⁴⁹⁵ was used as a putative indicator of vascular eNOS activity.

Results: (1) Vascular endothelium-dependent relaxation with acetylcholine in KKAY mice was improved by azilsartan treatment compared to candesartan cilexetil; (2) the ratio of Ser¹¹⁷⁷/Thr⁴⁹⁵ phosphorylation of eNOS was impaired in KKAY and was effectively restored by azilsartan; (3) anomalies in the expression levels of monocyte chemoattractant protein 1 (MCP1), F4/80, NAD(P)H oxidase (Nox) 2, and Nox4 of the aortic wall and in the expression of TNF α in the perivascular fat were strongly attenuated by azilsartan compared to candesartan cilexetil.

Conclusions: These results provide evidence that azilsartan prevents endothelial dysfunction in diabetic mice, more potently than does candesartan cilexetil. Azilsartan's higher affinity for and slower dissociation from AT1 receptors may underlie its efficacy in diabetic vascular dysfunction via a dual effect on uncoupled eNOS and on Nox.

Introduction

In patients with type 2 diabetes mellitus (T2DM), both macrovascular and microvascular disease cause extensive morbidity and mortality [1,2]. Treatment with angiotensin-converting enzyme inhibitors [3] and angiotensin II type 1 (AT1) receptor blockers (ARBs) [4] improves both macrovascular and microvascular outcomes in patients with T2DM. The renin-angiotensin system (RAS), a hormonal

cascade that includes angiotensinogen, renin, angiotensin-converting enzyme, angiotensin, and its receptors is involved in the maintenance of systemic blood pressure. Alternatively, angiotensin II functions as a local biologically active mediator in the progression of cardiovascular remodeling through the AT1 receptor [5]. Therefore, ARBs are thought to have cardioprotective effects beyond their antihypertensive effects. In a diabetic state, excessive systemic production of angiotensin II or predominant intracrine or intracellular RAS activation might be involved in the progression of vascular complications [6,7]. Therefore,

* Correspondence: mshimabukuro-ur@umin.ac.jp

²Department of Cardio-Diabetes Medicine, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto, Tokushima 770-8503, Japan

Full list of author information is available at the end of the article

elucidating effects and mechanisms of action of ARBs is crucial for understanding diabetic vascular complications.

Endothelial nitric oxide synthase (eNOS) is a nitric oxide synthase that generates nitric oxide (NO) in blood vessels and is involved with regulating vascular tone by inhibiting smooth muscle contraction [8]. Loss of NO bioavailability is believed to indicate a dysfunctional phenotype across broad properties of the endothelium. Thus, the assessment of its vasodilator properties resulting from NO can provide information on the integrity and function of the endothelium. Such endothelial dysfunction is implicated in the pathogenesis of cardiovascular diseases of type 2 diabetes [9].

Enzymatic activity of eNOS is regulated by multiple phosphorylation of specific sites on the eNOS protein [10]. The most well-studied are the functional consequences of phosphorylation of Ser¹¹⁷⁷ and Thr⁴⁹⁵. Ser¹¹⁷⁷ is a positive regulatory site of eNOS, and Thr⁴⁹⁵ is a negative regulatory site of eNOS in that phosphorylation leads to increase or decreased enzymatic activity [10]. It has been reported that drugs interfering with the renin-angiotensin-aldosterone system enhances eNOS phosphorylation at Ser¹¹⁷⁷ and improves NO bioavailability [11,12]. However, these beneficial effects of RAS blockade are not inspected in diabetic models. Reactive oxidant species (ROS), which are produced at a high rate in the diabetic and/or insulin resistant obese state [13], can cause oxidative damage of cellular components and activate several pathways linked with inflammation. RAS have been identified in different organs, most notably in those playing a significant role in metabolism and insulin sensitivity, including the liver, skeletal muscle and adipose and perivascular tissue. It has been reported that inhibition of RAS reduce ROS production pathways such as Nox2, a major catalytic component of an endothelial NADPH oxidase [14], and Nox4, a component of endothelial and smooth muscle NADPH oxidase [15], proinflammatory markers such as tumor necrosis factor α (TNF α) [16], monocyte chemoattractant protein 1 (MCP1) [16], F4/80 (a marker for mature macrophages and monocytes) [17] and improve adipocyte-expression of peroxisome proliferator-activated receptor γ_2 (PPAR γ_2), the ligand-activated nuclear hormone receptor [18], insulin receptor substrate 1 (IRS-1) [19], and adiponectin [20].

A new ARB, azilsartan, was recently approved and is expected to exert a more potent, sustained for 24 h BP-lowering effect compared to existing ARBs (candesartan cilexetil, olmesartan, telmisartan, valsartan, and irbesartan) [21]. In an *in vitro* study, it has been shown that azilsartan has higher affinity for and slower dissociation from AT1 receptors [22] and shows stronger inverse agonism [23]. These effects of azilsartan on the AT1 receptor may underlie its superior BP-lowering properties (compared to other ARBs) and may be beneficial in diabetic vascular remodeling.

The present study was designed to compare the efficacy of azilsartan and candesartan cilexetil against abnormalities

in vascular reactivity and eNOS phosphorylation (which reflects eNOS inactivation [24-26]) and against ROS and inflammatory activation in the vascular wall, perivascular fat, and skeletal muscle in a murine diabetic model.

Materials and methods

Animals and the protocol

Eight-week-old male KKAY mice (Clea Japan Inc., Tokyo, Japan) were randomly distributed into 3 treatment groups so that the groups had similar average blood glucose level and body weight. The mice were fed a standard moderate-fat (MF) diet or an MF diet mixed with 0.005% candesartan cilexetil or 0.005% azilsartan (Takeda Pharmaceutical Co., Ltd., Osaka, Japan) for 3 weeks (KKAY-Vehicle, KKAY-Azilsartan, and KKAY-Candesartan groups). Age-matched C57BL/6 J male mice (SLC Japan) were used as a control group (C57BL/6 J-Vehicle group). Based on a report showing that two-week treatment with candesartan cilexetil had a cardioprotective effects in 8-week-old KKAY mice [27], we chose a 3-week treatment period in 8-week old KKAY mice. Body weight, food intake, and systolic blood pressure were checked weekly. Blood pressure was measured using a tail cuff system (Softron, Co., Tokyo). At the end of the experimental period, we collected plasma, subcutaneous fat, visceral fat, liver, pancreas, soleus muscle, quadriceps muscle, thoracic aorta, and perivascular fat around the thoracic aorta and stored them at -80°C until analysis. Blood glucose levels were measured by a glucose meter, plasma insulin levels by a mouse insulin ELISA kit (Shibayagi Co.,Ltd., Gunma, Japan) and uric acid by a uric acid assay kit (Cayman Chemical, Ann Arbor, USA). Mice were housed in a light- and temperature-controlled room in a 12-hour light/dark cycle. All animal experiments were approved by the Committee on Animal Research, the University of Tokushima and have been conducted in accordance with international ethical principles and guidelines for experiments on animals.

The glucose tolerance test and insulin tolerance test

After 2 weeks of treatment, glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed. In GTT, the mice were given an intraperitoneal injection of 1 gram of glucose per kilogram of body weight after 16 hours of overnight fasting. Blood glucose levels were measured in 0, 15, 30, 60, 90, and 120 min. In ITT, the mice were given an injection of 0.75 or 1 unit of insulin per kilogram of body weight after 4 hours of fasting on post-GTT Day 3. Insulin sensitivity was estimated by percent changes in the plasma glucose concentration.

Vascular reactivity

The analysis of vascular reactivity was performed as described previously [28]. Briefly, the periadventitial tissue of the descending thoracic aorta was dissected away under

a stereomicroscope into the Krebs–Henseleit buffer (KHB; 118.4 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl₂, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 25 mM NaHCO₃, 11.1 mM glucose) and cut transversely into ~2.0-mm-long ring segments. The aortic rings were placed in a tissue chamber filled with KHB (37°C) bubbled with 90% O₂–5% CO₂ and were mounted onto 2 tungsten wires for measurement of isometric tension. Initial tension was set at 0.7 g, and the rings were allowed to equilibrate as the chambers were refilled with fresh KHB every 15 min. Cumulative concentration–response curves for acetylcholine (ACh; 10⁻⁹ M to 10⁻⁴ M) and sodium nitroprusside (SNP; 10⁻⁹ M to 10⁻⁴ M) were generated after induction of an approximately 60% contraction with phenylephrine (Phe) of maximal contraction caused by 31.4 mM KCl.

Western blotting analysis

For immunoblotting, we homogenized tissues in RIPA buffer (Wako Pure Chemical Industries, Ltd., Tokyo) containing protease inhibitors (Takara Bio Inc., Shiga, Japan) and a phosphatase inhibitor (Nacalai Tesque, Kyoto, Japan) and collected the supernatants. Proteins (5 µg/lane) were separated on 5–20% gradient SDS–polyacrylamide gels and transferred onto polyvinylidene difluoride membranes (GE Healthcare Bio Sciences, Piscataway, NJ). After blocking with TBS-T buffer containing either 3% bovine serum albumin or 5% skim milk, the membranes were incubated with antibodies against phospho-eNOS (Ser¹¹⁷⁷, 1:1000, Cell Signaling Technology, Beverly, MA), phospho-eNOS (Thr⁴⁹⁵, 1:1000, Cell Signaling Technology) and total eNOS (1:1000, BD Biosciences, San Diego, CA) or a peroxidase-conjugated antibody against β-actin (1:50000, Sigma–Aldrich, St. Louis, MO) [29] and antibody binding was detected with horseradish peroxidase-conjugated secondary antibodies (1:2000; Chemicon) using an enhanced chemiluminescence system (GE Healthcare Japan, Tokyo). The band intensity of phospho-eNOS (Ser¹¹⁷⁷ and Thr⁴⁹⁵) was scanned in gray scale at the maximum resolution of at least 600 dpi using NIH Image J 1.47 and arbitrary ratio normalized to the band intensity of total-eNOS were used.

Semiquantitative RT-PCR analysis

After extraction of total RNA from aorta, perivascular fat, and soleus muscle, we synthesized cDNA, using the QuantiTect Reverse Transcription kit (Qiagen, Valencia, CA) and then, performed real-time RT-PCR with gene-specific primers and SYBR green dye on an Applied Biosystems 7500 Real-Time PCR System (Life Technologies Japan Ltd, Tokyo). The forward (fwd) and reverse (rev) primer sequences are as follows: TNFα [30] (fwd: 5'-ACCCTCA CACTCAGATCATCTTC-3'; rev: 5'-TGGTGGTTTGCT ACGACGT-3'), MCP1 [30] (fwd: 5'-CCACTCACCTGC TGCTACTCAT-3'; rev: 5'-TGGTGATCCTCTTGTAGC TCTCC-3'), F4/80 [17] (fwd: 5'-TGCATCTAGCAATGG

ACAGC-3'; rev: 5'-GCCTTCTGGATCCATTGAA -3'), Nox2 [14] (fwd: 5'-ACTCCTTGGGTCAGCACTGG-3'; rev: 5'-GTTCTGTCCAGTTGTCTTGG-3'), Nox4 [15] (fwd: 5'-TGTTGGGCCTAGGATTGTGTT-3'; rev: 5'-AGGGACCTTCTGTGATCCTCG-3'), adiponectin (fwd: 5'-ATGGCAGAGATGGCACTCCT-3'; rev: 5'-CCTTC AGCTCCTGTCATTCCA-3'), PPAR_γ2 [18] (fwd: 5'-GAR GGAAGACCACTCGCATT-3'; rev: 5'-AACCATTTGGG TCAGCTCTTG -3'), IRS-1 [19] (fwd: 5'-GCCAGAGGA TCGTCAATAGC-3'; rev: 5'-AAGACGTGAGGTCCTGG TTG-3'), and β-actin (fwd: 5'-CCTGAGCGCAAGTACTC TGTGT-3'; rev: 5'-GTCGATCCACATCTGCTGGAA-3').

Statistical analysis

Data were calculated as mean ± SEM. All analyses were performed using the Prism software (version 6.0d, GraphPad Software, La Jolla, CA, USA). Two-way analysis of variance was used for the changes of systolic blood pressure and body weight in the course of administration, and for GTT and ITT. Differences between multiple groups were analyzed by one-way analysis of variance or the Kruskal–Wallis test in the case of non-Gaussian distribution, followed by the Tukey's *post hoc* test for comparison between treatment groups. Differences with *p* < 0.05 were considered statistically significant and with *p* < 0.01 significant.

Results

General characteristics

As shown in Table 1, body weight increased to the same extent in KKAY mice treated with vehicle, candesartan cilexetil, or azilsartan, and blood pressure was reduced comparably by candesartan cilexetil and azilsartan. In GTT, blood glucose levels in KKAY mice were higher at baseline and were strongly elevated after a glucose load compared to age-matched C57BL/6 J (Figure 1). In ITT, blood glucose levels did not decrease after an insulin injection in KKAY mice. Treatment with either candesartan cilexetil or azilsartan in KKAY mice did not change the response curves in GTT and ITT. Plasma levels of uric acid increased comparably in KKAY mice treated with vehicle, candesartan cilexetil, or azilsartan as compared to C57BL/6 J (Table 1). Weight of subcutaneous and visceral fat and of the liver was elevated and weight of the soleus and quadriceps muscles decreased in KKAY mice. Those metrics were not changed by candesartan cilexetil and azilsartan treatment (Table 1).

Effects on vascular function in KKAY mice

As shown in Figure 2, vascular endothelium–dependent relaxation in response to acetylcholine in KKAY mice was improved significantly by azilsartan, but not by candesartan cilexetil. The half-maximal effective concentration (EC₅₀) for acetylcholine was -8.06 ± 0.16 (log₁₀ mol/L) in vehicle-treated KKAY, -8.31 ± 0.16 in candesartan-treated

Table 1 General characteristics

		C57BL6J-Vehicle	KKAy-Vehicle	KKAy-Candesartan	KKAy-Azilsartan
Number		7	9	9	8
Body weight					
baseline	(g)	22.4 ± 0.4	36.5 ± 1.3	37.2 ± 1.6	37.0 ± 1.6
1 week	(g)	23.9 ± 0.6	41.2 ± 0.8	40.8 ± 0.9	41.3 ± 0.9
2 week	(g)	24.3 ± 0.6	40.5 ± 0.7	40.5 ± 0.9	40.6 ± 0.9
3 week	(g)	25.1 ± 0.8	43.8 ± 0.6	43.1 ± 0.9	43.0 ± 0.8
Systolic blood pressure					
baseline	(mmHg)	101 ± 1	101 ± 3	100 ± 2	102 ± 2
1 week	(mmHg)	100 ± 2	109 ± 2	82 ± 3	84 ± 3
2 week	(mmHg)	102 ± 1	104 ± 2	81 ± 2	82 ± 2
3 week	(mmHg)	99 ± 2	108 ± 2	79 ± 2	82 ± 3
Fasting blood glucose					
baseline	(mg/dL)	53 ± 4	75 ± 21	78 ± 8	77 ± 7
2 week	(mg/dL)	63 ± 4	139 ± 22	104 ± 10	138 ± 14
Plasma uric acid					
3 week	(μmol/L)	6.5 ± 1.8	18.7 ± 1.5	18.4 ± 3.0	18.0 ± 2.5
Tissue weight (g/g)					
subcutaneous fat/body weight		0.015 ± 0.002	0.040 ± 0.001	0.038 ± 0.002	0.042 ± 0.001
visceral fat/body weight		0.014 ± 0.001	0.025 ± 0.001	0.024 ± 0.001	0.028 ± 0.001
liver/body weight		0.047 ± 0.002	0.064 ± 0.002	0.058 ± 0.002	0.066 ± 0.001
soleus muscle/body weight		0.013 ± 0.000	0.008 ± 0.000	0.009 ± 0.000	0.007 ± 0.000
quadriceps muscle/body weight		0.014 ± 0.001	0.009 ± 0.000	0.010 ± 0.000	0.009 ± 0.000

Values are mean ± SEM. **p<0.01 vs KKAy-Vehicle. † p<0.05 and †† p<0.01 vs C57BL6J-Vehicle.

KKAy (p = 0.120 compared to vehicle), and -8.41 ± 0.14 in azilsartan-treated KKAy (p = 0.005 compared to vehicle). Constriction in response to phenylephrine and endothelium-independent relaxation in response to sodium nitroprusside did not differ among vehicle-, candesartan cilexetil-, and azilsartan-treated KKAy mice.

Effects on total eNOS and eNOS phosphorylation at Ser¹¹⁷⁷ and Thr⁴⁹⁵

Phosphorylation at Ser¹¹⁷⁷, a positive regulatory site of eNOS associated with increased enzymatic activity [10],

tended to be decreased, and phosphorylation at Thr⁴⁹⁵, a negative regulatory site of eNOS associated with decreased enzymatic activity [10], tended to be increased in KKAy mice compared to control mice (C57BL/6 J). Although changes in phosphorylation signals either at Ser¹¹⁷⁷ or Thr⁴⁹⁵ did not reach statistical significance, the ratio of phosphorylation at Ser¹¹⁷⁷ to phosphorylation at Thr⁴⁹⁵ was statistically significantly lower in KKAy mice (Figure 3). Compared to candesartan cilexetil, azilsartan was effective at restoring the phosphorylation ratio Ser¹¹⁷⁷/Thr⁴⁹⁵ (p < 0.05 compared to KKAy-vehicle).




Figure 1 Glucose tolerance test (GTT) and insulin tolerance test (ITT). GTT and ITT were performed in male KKAy mice fed standard moderate fat (MF) diet (KKAy-Vehicle, ○) and MF mixed with 0.005% candesartan cilexetil (KKAy-Candesartan groups, □) or 0.005% azilsartan (KKAy-Azilsartan, ●) for 2 weeks since 8–9 weeks of age. Age-matched C57BL/6 J male mice were used as a control group (△). The data are shown as mean ± SEM.




Figure 2 Vascular reactivity in aorta ring. Vascular reactivity to phenylephrine, acetylcholine, or sodium nitroprusside was determined using aortic rings isolated from male KKAY mice fed standard moderate fat (MF) diet (KKAY-Vehicle, ○) and MF mixed with 0.005% candesartan cilexetil (KKAY-Candesartan groups, □) or 0.005% azilsartan (KKAY-Azilsartan, ●) for 3 weeks since 8–10 weeks of age. Data represent the mean ± SEM. *p < 0.05, KKAY-vehicle versus KKAY-Azilsartan.

Effects on gene expression in aorta, perivascular fat, and soleus muscle

In the aortic wall of KKAY mice, mRNA expression of MCP1, a representative inflammatory cytokine [16], of F4/80, a marker for mature macrophages and monocytes [17], of Nox2, a major catalytic component of an endothelial NADPH oxidase [14], and of Nox4, a component of endothelial and smooth muscle NADPH oxidase [15], tended to be increased in KKAY mice compared to control mice (C57BL/6 J; Figure 4, upper panel). These levels of mRNA expression were strongly reduced by azilsartan compared to candesartan cilexetil. Expression of PPAR γ ₂, the ligand-activated nuclear hormone receptor [18], was decreased in KKAY, but was not altered by either candesartan cilexetil or azilsartan. In the perivascular fat, mRNA expression of TNF α , MCP1, and Nox2 was increased in KKAY

mice (Figure 4, middle panel), and these anomalies in the expression of TNF α and Nox2 were attenuated only by azilsartan. In the soleus muscle of KKAY, mRNA expression levels of TNF α , MCP1, and NOX2 were increased and that of IRS-1 [19] was decreased (p < 0.05 compared to the control group C57BL6J-Vehicle), and these anomalies of KKAY mice were not attenuated by either candesartan cilexetil or azilsartan (Figure 4, lower panel).

Discussion

The major findings of the present study are as follows: (1) vascular endothelium-dependent relaxation in response to acetylcholine in KKAY mice was improved strongly by azilsartan compared to candesartan cilexetil; (2) the ratio of Ser¹¹⁷⁷/Thr⁴⁹⁵ phosphorylation of eNOS, a putative marker for eNOS activation was impaired in KKAY mice, and the




Figure 3 Relative intensity of total eNOS and eNOS phosphorylation at Ser¹¹⁷⁷ (Ser¹¹⁷⁷p) and Thr⁴⁹⁵ (Thr⁴⁹⁵p) and the ratio of eNOS phosphorylation at Ser¹¹⁷⁷ to at Thr⁴⁹⁵ (Ser¹¹⁷⁷p/Thr⁴⁹⁵p; lower panel) in aorta. Using proteins (5 μ g/lane) of aorta isolated from male KKAY mice fed standard moderate fat (MF) diet (Veh) and MF mixed with 0.005% candesartan cilexetil (Can) or 0.005% azilsartan (Azi) for 3 weeks since 8–10 weeks of age, Western blotting analysis were made. Age-matched C57BL/6 J male mice were used as a control group. After transfer, the membranes were incubated with antibodies against phospho-eNOS (Ser¹¹⁷⁷, 1:1000, Cell Signaling Technology, Beverly, MA), phospho-eNOS (Thr⁴⁹⁵, 1:1000, Cell Signaling Technology) and total eNOS (1:1000, BD Biosciences, San Diego, CA) and antibody binding was detected with horseradish peroxidase-conjugated secondary antibodies (1:2000; Chemicon) using an enhanced chemiluminescence system (GE Healthcare Japan, Tokyo). The band intensity of phospho-eNOS (Ser¹¹⁷⁷ and Thr⁴⁹⁵) was scanned in gray scale at the maximum resolution of at least 600 dpi using NIH Image J 1.47 and arbitrary ratio normalized to the band intensity of total-eNOS were used. Data represent mean ± SEM. †p < 0.05 compared to C57BL/6 J and *p < 0.1 and *p < 0.05 compared to KKAY-vehicle, according to the Kruskal–Wallis test.




Figure 4 Gene expression in aorta (upper panel), perivascular fat (middle panel), and soleus muscle (lower panel). Samples isolated from male KKAY mice fed standard moderate-fat (MF) diet (black bars) and MF diet mixed with 0.005% candesartan cilexetil (gray bars) or 0.005% azilsartan (shaded bars) for 3 weeks since 8–10 weeks of age, were analyzed by semiquantitative RT-PCR. *Gapdh* was used as an internal control. Values shown represent mean \pm SEM ($n = 4-6$). † $p < 0.05$ compared to C57BL/6 J and ‡ $p < 0.1$ and * $p < 0.05$ compared to KKAY-vehicle according to either the Kruskal–Wallis test or unpaired *t* test. TNF α : tumor necrosis factor α ; MCP1: monocyte chemoattractant protein 1; PPAR γ_2 : peroxisome proliferator-activated receptor γ_2 ; IRS-1: insulin receptor substrate 1; and Adipo: adiponectin.

healthy ratio was effectively restored by azilsartan compared to candesartan cilexetil; (3) the differences in the expression levels of MCP1, F4/80, Nox2, and Nox4 of the aortic wall and in the expression of TNF α in the perivascular fat were attenuated by azilsartan compared to candesartan cilexetil. These data suggest that azilsartan restores endothelial function more effectively than does candesartan cilexetil, by normalizing eNOS function and by reducing inflammation and oxidative stress in diabetic mice.

Vascular endothelial dysfunction is implicated in the pathogenesis of cardiovascular diseases [24] and is well known to occur in obesity [31] and type 2 diabetes [9]. The present study compared the efficacy of azilsartan and candesartan cilexetil on vascular reactivity, which reflects eNOS inactivation [24–26], and we measured phosphorylation of vascular eNOS as an indicator of eNOS activity. Enzymatic activity of eNOS is regulated by multiple phosphorylation of specific sites on the eNOS protein [10]. When Ser¹¹⁷⁷ is phosphorylated, nitric oxide production is increased 2- to 3-fold. In contrast, Thr⁴⁹⁵ is a negative regulatory site of eNOS in that phosphorylation

leads to decreased enzymatic activity [10]. It has been reported that phosphorylation of Ser¹¹⁷⁷-eNOS is decreased in diabetic rats [32] and diabetic patients [33]. Inversely, eNOS phosphorylation at Ser⁴⁹⁵ was reported to be increased in *db/db* diabetic mice [34]. These data are consistent with our results showing that diabetic KKAY mice have a tendency for lower phosphorylation at Ser¹¹⁷⁷ and stronger phosphorylation at Thr⁴⁹⁵; these mice show a significantly decreased phosphorylation ratio of Ser¹¹⁷⁷ to Thr⁴⁹⁵ on eNOS compared to control C57BL/6 mice. The Ser¹¹⁷⁷/Thr⁴⁹⁵ ratio was effectively normalized (increased) by azilsartan treatment compared to candesartan cilexetil. The kinases AMPK, Akt, protein kinase A (PKA), calmodulin/Ca²⁺ dependent protein kinase (CaMKII), protein kinase G (PKG) and the phosphatase protein phosphatase 2A (PP2A) have all been implicated in the regulation of eNOS-Ser¹¹⁷⁷ phosphorylation [10], while protein kinase C (PKC) has been shown to phosphorylate eNOS-Thr⁴⁹⁵. In addition, there is evidence for co-ordination between dephosphorylation of eNOS-Thr⁴⁹⁵ and activating phosphorylation of eNOS-Ser¹¹⁷⁷ [35]. The mechanism(s)

for the alteration of phosphorylation at Ser¹¹⁷⁷ and Thr⁴⁹⁵ in the diabetic state are largely unknown, however, altered signaling in AMPK, Akt, PKA, CaMKII, PKG, PP2A, and PKC in the diabetic state could be involved in the deregulated eNOS phosphorylation.

In the aortic wall of KKAY mice, mRNA expression levels of MCP1 and F4/80 tended to be increased, suggestive of overproduction of proinflammatory cytokines by activated macrophages/monocytes. Such proinflammatory cytokines frequently cause overproduction of ROS via excessive stimulation of reduced nicotinamide adenine dinucleotide phosphate [36]. Cellular sources of ROS include NADPH-dependent oxidases, xanthine oxidase, lipoxigenases, mitochondrial oxidases, and NO synthases [37]. NADPH oxidase (Nox) is a major source of ROS in diabetic humans [38] and diabetic animals [39]. Seven isoforms of Nox have been described in mammals [36]. Each isoform contains a core catalytic subunit, i.e., Nox1–Nox5 and dual oxidase (DUOX) 1 and DUOX 2 [36]. Each Nox catalytic isoform contains up to 5 regulatory subunits that determine 1) maturation and expression of Nox and DUOX subunits in biological membranes, 2) enzyme activation, and 3) spatial organization. In our study, mRNA expression levels of Nox2 (gp91phox), the major catalytic component of endothelial NADPH oxidase, and Nox4, a component of endothelial and smooth muscle NADPH oxidase [36], were increased, suggesting that ROS production is increased via overexpression of Nox2 and Nox4 in KKAY mice. Reportedly, a siRNA-mediated knockdown of Nox2 (which is upregulated in diabetic endothelial cells) reduces ROS production and improves vascular function [14]. It has also been reported that Nox4 is upregulated in an animal diabetic model [40] or as a result of hyperglycemia [41], with a concomitant increase in ROS. Taken together, upregulation of Nox2 and/or Nox4 in the aorta may be linked to ROS overproduction and vascular dysfunction in our murine model of diabetes.

The upregulation of ROS-producing Nox2 and Nox4 was decreased strongly by azilsartan as compared to candesartan cilexetil, according to the present results. We could not determine whether the greater inhibition of aortic Nox2 and Nox4 expression by azilsartan significantly sensitizes endothelial vasodilator response to acetylcholine. Angiotensin II levels are increased in patients with diabetes [42] and hyperglycemia potently upregulated expression of the angiotensin II type 1 receptor (AT1) [43]; thus, both could sensitize vascular cells to angiotensin II. Oak and Cai reported that streptozotocin-induced diabetes in mice is characterized by a marked increase in aortic ROS production, which is inhibited by NG-nitro-L-arginine methyl ester hydrochloride (L-NAME, inhibitor of nitric oxide synthase) in contrast to nondiabetic controls, indicating uncoupling of eNOS in the diabetic state [44]. According to their data, angiotensin II receptor

type 1 blocker candesartan decreased eNOS-derived ROS while augmenting nitric oxide bioavailability in diabetic aortas, which is suggestive of recoupling of eNOS. Nox activity was more than doubled in the endothelium-denuded diabetic aortas but this effect was attenuated by candesartan, indicating that Nox remains active in nonendothelial vascular tissues, although uncoupled eNOS is responsible for endothelial production of O₂. They concluded that the dual effect on uncoupled eNOS and Nox might explain the high efficacy of angiotensin II antagonists in restoring endothelial function [44].

Going back to our results, because azilsartan has higher affinity for and slower dissociation from AT1 receptors [22] and shows stronger inverse agonism [23], these effects of azilsartan on AT1 receptor, as compared with candesartan cilexetil, may underlie the superior efficacy in diabetic vascular dysfunction via the dual effect on uncoupled eNOS and Nox. There is a report showing that angiotensin II-induced contraction was augmented in aorta rings isolated from diabetic rats and suggesting that the enhanced functional coupling of AT1 receptors results in supersensitivity to Ang II [45]. The higher affinity of azilsartan for AT1 receptors may be beneficial for protecting angiotensin II-induced vascular remodeling in the diabetic condition [42]. Clinical studies have exhibited that some benefits conferred by ARBs may not be class effects, but rather molecular effects [46]. It was shown in a clinical study that in losartan users uric acid levels decrease from baseline, while they increase in users of other ARBs like valsartan, telmisartan, candesartan, and olmesartan [47]. Among these ARBs, losartan uniquely exhibits a cis-inhibitory effect on the uptake of uric acid by the renal uric acid transporter (URAT1) [48]. Partial chemical structures for the URAT1 competitive binding may involve an AT1 receptor-independent mechanism of action [48]. In our study, plasma levels of uric acid increased comparably in KKAY mice treated with vehicle, candesartan cilexetil, or azilsartan as compared to C57BL/6 J, indicating no difference in uric acid metabolism between two ARBs. It has been reported that genetic disruption or pharmacological inhibition by telmisartan of the AT1R attenuates atherosclerosis and improves endothelial function in diabetic ApoE^{-/-} mice via the PPAR γ pathway [49]. In 3 T3-L1 preadipocytes, azilsartan enhanced adipogenesis as well as effects on expression of PPAR α , PPAR δ , leptin, adiponectin, and adiponectin [50]. Azilsartan also potently inhibited vascular cell proliferation in the absence of exogenously supplemented angiotensin II or in cells lacking AT1 receptors [50]. These findings suggest that azilsartan can function as a pleiotropic ARB with beneficial effects on actions that could involve more than just blockade of AT1 receptors and/or beyond their antihypertensive effects.

In the perivascular fat, mRNA expression levels of TNF α , MCP1, and Nox2 were increased in KKAY, and the overexpression of TNF α and Nox2 was attenuated

only by azilsartan. Aortic expression of PPAR γ ₂ was decreased in KKAY, but was not altered by candesartan cilexetil and azilsartan. We previously demonstrated that adiponectin secreted from perivascular adipose tissue has a protective role in neointimal formation after endovascular injury thanks to its anti-inflammatory properties, whereas perivascular adipose tissue-secreted TNF α plays an adverse atherogenic role in neointimal formation because of its proinflammatory effects [51,52]. Kurata et al. reported that blockade of angiotensin II receptor ameliorates adipocytokine dysregulation and that such action is mediated, at least in part, by a reduction of oxidative stress in accumulated adipose tissue [20]. In agreement with the previous report, mRNA expression of TNF α , MCP1, and Nox2 was increased in the perivascular fat from KKAY mice, and these anomalies in the expression of TNF α and Nox2 were attenuated only by azilsartan. Although the current study could not verify the direct link between vascular dysfunction and attenuation of adipocytokine dysregulation in perivascular fat, the possible role of perivascular fat in azilsartan-induced vascular remodeling should be assessed in future studies.

Although weight in the liver was increased, weight in the soleus and quadriceps muscle was decreased in the KKAY mice. A relative decrease of muscle mass as compared to body weight fails to metabolize abundant fat and worsens fat accumulation in the liver. Abundant fat with concomitant metabolic derangement underlies vascular dysfunction in the KKAY diabetic mice [53,54]. In the soleus muscle of KKAY, mRNA expression levels of TNF α , MCP1, and Nox2 were increased and IRS-1 was decreased, but this overexpression was not attenuated by either candesartan cilexetil or azilsartan. It has been shown that azilsartan reduced left ventricular hypertrophy, cardiac fibrosis, plasminogen activator inhibitor-1 (PAI-1; a marker of profibrosis) in aortic banding mice fed high-fat diet [55], indicating that azilsartan may exert favorable biological effects in non-diabetic obese insulin-resistant condition, which shares a common mechanism such as enhanced ROS/inflammation signals with the current model.

Conclusions

Our data suggest that azilsartan restores endothelial function more effectively than does candesartan cilexetil, by normalizing eNOS function and by reducing inflammation and oxidative stress in diabetic mice.

Abbreviations

AT1: Angiotensin II type 1 (AT1) receptor; ROS: Reactive oxygen species; NAD(P)H: Nicotinamide adenine dinucleotide phosphate; Nox: NAD(P)H oxidase; eNOS: Endothelial nitric oxide synthase; L-NAME: N^G-nitro-L-arginine methyl ester; TNF α : Tumor necrosis factor- α ; MCP1: Monocyte chemoattractant protein 1; PPAR γ : Peroxisome proliferator-activated receptor- γ ; IRS-1: Insulin receptor substrate 1.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SM designed and performed study, MiS designed the study and wrote the manuscript, DF and TS were involved in discussions, KY and HM participated in vascular function study, and MaS designed and supervised this study. All authors read and approved the final manuscript.

Acknowledgement

We deeply appreciate Dr. Toshihiro Matsuzaki, Department of Pharmacology, Graduate School of Medicine, University of the Ryukyus for valuable advice in vascular function study.

Sources of funding

This work was supported by JSPS KAKENHI Grant Number 60271144 (MiS), JSPS KAKENHI Grant Number 25460369 (DF), and MEXT KAKENHI Grant Number 21117007, JSPS KAKENHI Grant Numbers 24659392, 22390159, 25670390, and 25293184 (MaS).

Author details

¹Department of Cardiovascular Medicine, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto, Tokushima 770-8503, Japan. ²Department of Cardio-Diabetes Medicine, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto, Tokushima 770-8503, Japan. ³Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.

Received: 25 November 2013 Accepted: 23 January 2014

Published: 31 January 2014

References

1. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C: **Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.** *BMJ* 2011, **343**:d4169.
2. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, et al: **Diabetes mellitus, fasting glucose, and risk of cause-specific death.** *N Engl J Med* 2011, **364**(9):829–841.
3. Investigators HOPEHS: **Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.** *Lancet* 2000, **355**(9200):253–259.
4. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, et al: **Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.** *Lancet* 2002, **359**(9311):1004–1010.
5. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlöf B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W, et al: **The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data.** *Am J Cardiol* 2001, **88**(9a):11–20.
6. Kumar R, Yong QC, Thomas CM, Baker KM: **Intracardiac intracellular angiotensin system in diabetes.** *Am J Physiol Regul Integr Comp Physiol* 2012, **302**(5):R510–R517.
7. van der Zijl NJ, Moors CC, Goossens GH, Blaak EE, Diamant M: **Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms.** *Diabetes Obes Metab* 2012, **14**(7):586–595.
8. Förstermann U, Münzel T: **Endothelial nitric oxide synthase in vascular disease: From Marvel to Menace.** *Circulation* 2006, **113**(13):1708–1714.
9. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, et al: **Mechanisms underlying endothelial dysfunction in diabetes mellitus.** *Circ Res* 2001, **88**(2):E14–E22.
10. Mount PF, Kemp BE, Power DA: **Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation.** *J Mol Cell Cardiol* 2007, **42**(2):271–279.

11. Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T: **Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability.** *Hypertension* 2008, **51**(3):734–741.
12. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H, Tanimoto T, Muragaki Y, Mochizuki S, Goto M, et al: **Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.** *Hypertension* 2008, **52**(3):563–572.
13. Giacco F, Brownlee M: **Oxidative stress and diabetic complications.** *Circ Res* 2010, **107**(9):1058–1070.
14. Sukumar P, Viswambharan H, Imrie H, Cubbon RM, Yuldasheva N, Gage M, Galloway S, Skromna A, Kandavelu P, Santos CX, et al: **Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction.** *Diabetes* 2013, **62**(6):2130–2134.
15. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, Wakisaka M, Ibayashi S, Utsumi H, Iida M: **Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase.** *Circulation* 2004, **109**(2):227–233.
16. Aroor AR, McKarns S, Demarco VG, Jia G, Sowers JR: **Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.** *Metab Clin Exp* 2013, **62**(11):1543–1552.
17. Lin HH, Stacey M, Stein-Streilein J, Gordon S: **F4/80: the macrophage-specific adhesion-GPCR and its role in immunoregulation.** *Adv Exp Med Biol* 2010, **706**:149–156.
18. Pelham CJ, Keen HL, Lentz SR, Sigmund CD: **Dominant negative PPAR γ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle.** *Am J Physiol Regul Integr Comp Physiol* 2013, **304**(9):R690–R701.
19. Sarfstein R, Werner H: **Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction.** *Endocrinology* 2013, **154**(5):1672–1679.
20. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse T, Fujita K, Yasui A, et al: **Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation.** *Kidney Int* 2006, **70**(10):1717–1724.
21. Kurtz TW, Kajiya T: **Differential pharmacology and benefit/risk of azilsartan compared to other sartans.** *Vasc Health Risk Manag* 2012, **8**:133–143.
22. Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, Kubo K, Fuse H, Imura Y, Kusumoto K, et al: **In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies.** *J Pharm Exp Ther* 2011, **336**(3):801–808.
23. Miura S, Okabe A, Matsuo Y, Karnik SS, Saku K: **Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan.** *Hypertens Res* 2013, **36**(2):134–139.
24. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Luscher TF, Shechter M, Taddei S, et al: **The assessment of endothelial function: from research into clinical practice.** *Circulation* 2012, **126**(6):753–767.
25. Zhang YH, Casadei B: **Sub-cellular targeting of constitutive NOS in health and disease.** *J Mol Cell Cardiol* 2012, **52**(2):341–350.
26. Kolluru GK, Siamwala JH, Chatterjee S: **eNOS phosphorylation in health and disease.** *Biochimie* 2010, **92**(9):1186–1198.
27. Yu F, Chen R, Takahashi T, Sumino H, Morimoto S, Nakahashi T, Iwai K, Matsumoto M, Kanda T: **Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin.** *Int J Cardiol* 2008, **129**(3):414–421.
28. Chinen I, Shimabukuro M, Yamakawa K, Higa N, Matsuzaki T, Noguchi K, Ueda S, Sakanashi M, Takasu N: **Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats.** *Endocrinology* 2007, **148**(1):160–165.
29. Sonveaux P, Martinive P, DeWever J, Batova Z, Daneau G, Pelat M, Ghisidal P, Gregoire V, Dessy C, Balligand JL, et al: **Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis.** *Circ Res* 2004, **95**(2):154–161.
30. Hopkins PN: **Molecular biology of atherosclerosis.** *Physiol Rev* 2013, **93**(3):1317–1542.
31. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD: **Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance.** *J Clin Invest* 1996, **97**(11):2601–2610.
32. Zhang H, Zhang J, Ungvari Z, Zhang C: **Resveratrol improves endothelial function: role of TNF α and vascular oxidative stress.** *Arterioscler Thromb Vasc Biol* 2009, **29**(8):1164–1171.
33. Streit U, Reuter H, Bloch W, Wahlers T, Schwinger RH, Brixius K: **Phosphorylation of myocardial eNOS is altered in patients suffering from type 2 diabetes.** *J Appl Physiol* 2013, **114**(10):1366–1374.
34. Mordwinkin NM, Meeks CJ, Jadhav SS, Espinoza T, Roda N, diZerega GS, Louie SG, Rodgers KE: **Angiotensin-(1-7) administration reduces oxidative stress in diabetic bone marrow.** *Endocrinology* 2012, **153**(5):2189–2197.
35. Michell BJ, Chen Z, Tiganis T, Stapleton D, Katsis F, Power DA, Sim AT, Kemp BE: **Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase.** *J Biol Chem* 2001, **276**(21):17625–17628.
36. Bedard K, Krause KH: **The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology.** *Physiol Rev* 2007, **87**(1):245–313.
37. Guzik TJ, Harrison DG: **Vascular NADPH oxidases as drug targets for novel antioxidant strategies.** *Drug Discov Today* 2006, **11**(11–12):524–533.
38. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM: **Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase.** *Circulation* 2002, **105**(14):1656–1662.
39. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: **Increased oxidative stress in obesity and its impact on metabolic syndrome.** *J Clin Invest* 2004, **114**(12):1752–1761.
40. Meng D, Mei A, Liu J, Kang X, Shi X, Qian R, Chen S: **NADPH oxidase 4 mediates insulin-stimulated HIF-1 α and VEGF expression, and angiogenesis in vitro.** *PLoS One* 2012, **7**(10):e48393.
41. Patel H, Chen J, Das KC, Kavdia M: **Hyperglycemia induces differential change in oxidative stress at gene expression and functional levels in HUVEC and HMVEC.** *Cardiovasc Diabetol* 2013, **12**(1):142.
42. Burnier M, Zanchi A: **Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.** *J Hypertens* 2006, **24**(1):11–25.
43. Sodhi CP, Kanwar YS, Sahai A: **Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells.** *Am J Physiol Heart Circ Physiol* 2003, **284**(3):H846–H852.
44. Oak JH, Cai H: **Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice.** *Diabetes* 2007, **56**(1):118–126.
45. Arun KH, Kaul CL, Ramarao P: **AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats.** *Cardiovasc Res* 2005, **65**(2):374–386.
46. Miura S, Karnik SS, Saku K: **Angiotensin II type 1 receptor blockers: class effects versus molecular effects.** *J Renin Angiotensin Aldosterone Syst* 2010, **12**(1):1–7.
47. Nishida Y, Takahashi Y, Susa N, Kanou N, Nakayama T, Asai S: **Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.** *Cardiovasc Diabetol* 2013, **12**(1):159.
48. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I: **Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.** *J Pharm Exp Ther* 2007, **320**(1):211–217.
49. Tiyerili V, Becher UM, Aksoy A, Lutjohann D, Wassmann S, Nickenig G, Mueller CF: **AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPAR γ .** *Cardiovasc Diabetol* 2013, **12**:30.
50. Kajiya T, Ho C, Wang J, Vilardi R, Kurtz TW: **Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker.** *J Hypertens* 2011, **29**(12):2476–2483.
51. Takaoka M, Nagata D, Kihara S, Shimomura I, Kimura Y, Tabata Y, Saito Y, Nagai R, Sata M: **Periadventitial adipose tissue plays a critical role in vascular remodeling.** *Circ Res* 2009, **105**(9):906–911.
52. Takaoka M, Suzuki H, Shioda S, Sekikawa K, Saito Y, Nagai R, Sata M: **Endovascular injury induces rapid phenotypic changes in perivascular adipose tissue.** *Arterioscler Thromb Vasc Biol* 2010, **30**(8):1576–1582.
53. Shimabukuro M: **Cardiac adiposity and global cardiometabolic risk: new concept and clinical implication.** *Circ J* 2009, **73**(1):27–34.

54. Shimabukuro M, Kozuka C, Taira S, Yabiku K, Dagvasumberel M, Ishida M, Matsumoto S, Yagi S, Fukuda D, Yamakawa K, *et al*: Ectopic fat deposition and global cardiometabolic risk: new paradigm in cardiovascular medicine. *J Med Invest* 2013, **60**(1-2):1-14.
55. Tarikuz Zaman AK, McLean DL, Sobel BE: The efficacy and tolerability of azilsartan in obese insulin-resistant mice with left ventricular pressure overload. *J Cardiovasc Pharmacol* 2013, **62**(4):381-387.

doi:10.1186/1475-2840-13-30

Cite this article as: Matsumoto *et al*: Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser¹¹⁷⁷/Thr⁴⁹⁷ of endothelial nitric oxide synthase in diabetic mice. *Cardiovascular Diabetology* 2014 **13**:30.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

